Methotrexate is a JAK/STAT pathway inhibitor

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Thomas, Sally ^a   Fisher, Katherine H ^a   Snowden, John A ^a,b   Danson, Sarah J ^a,c   Brown, Stephen ^a   Zeidler, Martin P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN C JUN; PROTEIN KINASE B; RUXOLITINIB; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; ENZYME INHIBITOR;

ADULT; AGED; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE ACTIVITY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

DROSOPHILA MELANOGASTER;

ANIMALS; DROSOPHILA MELANOGASTER; ENZYME INHIBITORS; JANUS KINASE 2; METHOTREXATE; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84938838439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130078     Document Type: Article

References (51)

1. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322. PMID: 9597132
2. Arbouzova NI, Zeidler MP (2006) JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions. Development 133: 2605-2616. PMID: 16794031
3. O'Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28: 477-487. doi: 10.1016/j.immuni.2008.03.002 PMID: 18400190
4. O'Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36: 542-550. doi: 10.1016/j.immuni.2012.03.014 PMID: 22520847
5. O'Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368: 161-170. doi: 10.1056/NEJMra1202117 PMID: 23301733
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061. PMID: 15781101
7. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148. PMID: 15793561
8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790. PMID: 15858187
9. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397. PMID: 15837627
10. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L et al. (2012) Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 119: 3550-3560. doi: 10.1182/blood-2011-12-397554 PMID: 22234689
11. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798. doi: 10.1056/NEJMoa1110556 PMID: 22375970
12. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS et al. (2014) Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol 167(3): 418-420. doi: 10.1111/bjh.12985 PMID: 24961987
13. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T et al. (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123: 1833-1835. doi: 10.1182/blood-2013-12-544411 PMID: 24443442
14. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E et al. (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120: 513-520. PMID: 24258498
15. Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D et al. (2013) Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. Pharmacoeconomics 31: 841-852. doi: 10.1007/s40273-013-0083-0 PMID: 23996108
16. Farber S, Diamond LK (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238: 787-793. PMID: 18860765
17. Li JC, Kaminskas E (1984) Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc Natl Acad Sci U S A 81: 5694-5698. PMID: 6592582
18. Bookbinder SA, Espinoza LR, Fenske NA, Germain BF, Vasey FB (1984) Methotrexate: its use in the rheumatic diseases. Clin Exp Rheumatol 2: 185-193. PMID: 6398173
19. Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57: 163-172. PMID: 15914465
20. Wessels JA, Huizinga TW, Guchelaar HJ (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47: 249-255.
21. Echalier G, Ohanessian A (1969) [Isolation, in tissue culture, of Drosophila melangaster cell lines]. C R Acad Sci Hebd Seances Acad Sci D 268: 1771-1773. PMID: 4976834
22. Stec W, Vidal O, Zeidler MP (2013) Drosophila SOCS36E negatively regulates JAK/STAT pathway signaling via two separable mechanisms. Mol Biol Cell 24: 3000-3009. doi: 10.1091/mbc.E13-05-0275 PMID: 23885117
23. Levitzki A (1990) Tyrphostins - potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 40: 913-918. PMID: 2143901
24. Fisher KH, Wright VM, Taylor A, Zeidler MP, Brown S (2012) Advances in genome-wide RNAi cellular screens: a case study using the Drosophila JAK/STAT pathway. BMC Genomics 13: 506. doi: 10.1186/1471-2164-13-506 PMID: 23006893
25. Müller P, Kuttenkeuler D, Gesellchen V, Zeidler MP, Boutros M (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature 436: 871-875. PMID: 16094372
26. (2005) American Hospital Formulary Service - Drug Information. In: McEvoy GK, editor. Bethesda: American Society of Health-System Pharmacists.
27. Jelkmann W (2009) Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant 24: 1366-1368. doi: 10.1093/ndt/gfp058 PMID: 19225013
28. Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100: 4272-4290. PMID: 12393615
29. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B (2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77: 10288-10294. PMID: 12970413
30. Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N (1995) Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J 14: 2857-2865. PMID: 7796812
31. Cochet O, Frelin C, Peyron JF, Imbert V (2006) Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 18: 449-455. PMID: 15967637
32. Kim BH, Oh SR, Yin CH, Lee S, Kim EA, Kim MS et al. (2010) MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol 148: 132-143. doi: 10.1111/j.1365-2141.2009.07925.x PMID: 19793252
33. Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A et al. (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121: 5145-5153. doi: 10.1182/blood-2013-01-480335 PMID: 23652803
34. Hobl EL, Mader RM, Jilma B, Duhm B, Mustak M, Bröll H et al. (2012) A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naive adult patients with rheumatoid arthritis. Clin Ther 34: 1195-1203. doi: 10.1016/j.clinthera.2012.03.059 PMID: 22516039
35. Anand S, Stedham F, Gudgin E, Campbell P, Beer P, Green AR et al. (2011) Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 118: 1610-1621. doi: 10.1182/blood-2011-02-335042 PMID: 21653937
36. Whittle SL, Hughes RA (2004) Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43: 267-271.
37. Dixon KH, Trepel JB, Eng SC, Cowan KH (1991) Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. Cancer Commun 3: 357-365. PMID: 16296001
38. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367: 495-507. doi: 10.1056/NEJMoa1109071 PMID: 22873530
39. Rosenthal A, Mesa RA (2014) Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opin Pharmacother 15: 1265-1276. doi: 10.1517/14656566.2014.913024 PMID: 24766055
40. Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N et al. (2010) Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug metabolism and disposition: the biological fate of chemicals 38: 2023-2031.
41. Visentin M, Zhao R, Goldman ID (2012) The antifolates. Hematol Oncol Clin North Am 26: 629-48, ix. doi: 10.1016/j.hoc.2012.02.002 PMID: 22520983
42. Walker JG, Smith MD (2005) The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 32: 1650-1653. PMID: 16142855
43. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M et al. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5: 1731-1740. PMID: 16102523
44. Bain BJ, Ahmad S (2014) Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 166: 809-817. doi: 10.1111/bjh.12963 PMID: 24913195
45. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. (2012) Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366: 1905-1913. doi: 10.1056/NEJMoa1114885 PMID: 22591296
46. Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K et al. (2012) STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120: 3048-3057. doi: 10.1182/blood-2012-06-435297 PMID: 22859607
47. Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Novak AJ, Ansell SM (2014) Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia. Blood 123: 1055-1058. doi: 10.1182/blood-2013-08-521963 PMID: 24335105
48. Warsch W, Walz C, Sexl V (2013) JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 122: 2167-2175. doi: 10.1182/blood-2013-02-485573 PMID: 23926299
49. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I et al. (2014) Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123: 3797-3802. doi: 10.1182/blood-2013-10-534073 PMID: 24778152
50. Lamy T, Loughran TPJ (2011) How I treat LGL leukemia. Blood 117: 2764-2774. doi: 10.1182/blood-2010-07-296962 PMID: 21190991
51. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H et al. (2014) Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 99: 292-298. doi: 10.3324/haematol.2013.087650 PMID: 23911705